# Nuvation Bio Inc.: overview NUVB · NYSE · CIK 1811063 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nuvb.md) · [Financials](/companies/nuvb/financials.md) · [Filings](/companies/nuvb/filings.md) · [Insiders](/companies/nuvb/insiders.md) Latest reported revenue: [$31.7m](/filings/0001193125-26-336646.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-336646). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.7](/filings/0001193125-25-262605.md) | [5.7 d](/filings/0001193125-26-085584.md) | [3.1](/filings/0001193125-26-203964.md) | [4.8](/filings/0001193125-26-336646.md) | [13.1](/filings/0001193125-25-262605.md) | [41.9 d](/filings/0001193125-26-085584.md) | [83.2](/filings/0001193125-26-203964.md) | [31.7](/filings/0001193125-26-336646.md) | | Gross margin | % | [(108.4%)](/filings/0001193125-25-262605.md) | [26.2% d](/filings/0000950170-25-034903.md) | [32.1%](/filings/0000950170-25-065712.md) | [46.7%](/filings/0000950170-25-104626.md) | [74.5%](/filings/0001193125-25-262605.md) | not reported | not reported | not reported | | Operating margin | % | [(6616.4%)](/filings/0001193125-25-262605.md) | [(944.5%) d](/filings/0001193125-26-085584.md) | [(1913.2%)](/filings/0001193125-26-203964.md) | [(1315.7%)](/filings/0001193125-26-336646.md) | [(430.1%)](/filings/0001193125-25-262605.md) | [(81.3%) d](/filings/0001193125-26-085584.md) | [4.7%](/filings/0001193125-26-203964.md) | [(161.1%)](/filings/0001193125-26-336646.md) | | Net margin | % | [(5668.5%)](/filings/0001193125-25-262605.md) | [(865.8%) d](/filings/0001193125-26-085584.md) | [(1726.2%)](/filings/0001193125-26-336646.md) | [(1220.9%)](/filings/0001193125-26-336646.md) | [(425.2%)](/filings/0001193125-25-262605.md) | [(87.4%) d](/filings/0001193125-26-085584.md) | [6.5%](/filings/0001193125-26-336646.md) | [(198.3%)](/filings/0001193125-26-336646.md) | | Diluted EPS | $ per share | [(0.15)](/filings/0001193125-25-262605.md) | not reported | [(0.16)](/filings/0001193125-26-203964.md) | [(0.17)](/filings/0001193125-26-336646.md) | [(0.16)](/filings/0001193125-25-262605.md) | not reported | [0.01](/filings/0001193125-26-203964.md) | [(0.18)](/filings/0001193125-26-336646.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-034903.md) | [7.9](/filings/0001193125-26-085584.md) | [62.9](/filings/0001193125-26-085584.md) | | Gross margin | % | not reported | not reported | not reported | [10.1%](/filings/0000950170-25-034903.md) | not reported | | Operating margin | % | not reported | not reported | not reported | [(7527.3%)](/filings/0001193125-26-085584.md) | [(338.7%)](/filings/0001193125-26-085584.md) | | Net margin | % | not reported | not reported | not reported | [(7213.8%)](/filings/0001193125-26-085584.md) | [(325.3%)](/filings/0001193125-26-085584.md) | | Diluted EPS | $ per share | [(0.44)](/filings/0000950170-23-008180.md) | [(0.48)](/filings/0000950170-24-023247.md) | [(0.35)](/filings/0000950170-25-034903.md) | [(2.11)](/filings/0001193125-26-085584.md) | [(0.60)](/filings/0001193125-26-085584.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nuvb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $296.7m | 52,230,295 | | Added +240,702 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $156.9m | 27,630,837 | | Added +2,530,463 | | [Decheng Capital LLC](/funds/2010850.md) | 2026-06-30 | $147.4m | 25,954,439 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $67.7m | 11,919,514 | | Added +293,316 | | [Omega Fund Management, LLC](/funds/1637359.md) | 2026-06-30 | $45.9m | 8,081,089 | | Unchanged | | [Laurion Capital Management LP](/funds/1390202.md) | 2026-06-30 | $44.4m | 7,820,013 | | Reduced −2,625 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $41.9m | 7,370,794 | | Added +585,867 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $36.2m | 6,374,705 | Call | New +6,374,705 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $35.5m | 6,244,805 | | Added +381,151 | | [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $25.6m | 4,499,643 | | Added +1,602,565 | ## Recent filings [All 396 filings](/companies/nuvb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 07:30 ET | [8-K](/filings/0001193125-26-336751.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336751 | | 2026-08-06 | 06:55 ET | [10-Q](/filings/0001193125-26-336646.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336646 | | 2026-07-06 | 17:15 ET | [8-K](/filings/0001193125-26-296398.md) | 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-296398 | | 2026-06-30 | 17:17 ET | [8-K](/filings/0001193125-26-290823.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-290823 | | 2026-05-27 | 16:16 ET | [8-K](/filings/0001193125-26-241922.md) | 5.07 Shareholder vote results | 0001193125-26-241922 | | 2026-05-04 | 16:21 ET | [8-K](/filings/0001193125-26-204056.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-204056 | | 2026-05-04 | 16:06 ET | [10-Q](/filings/0001193125-26-203964.md) | Quarterly report, period 2026-03-31 | 0001193125-26-203964 | | 2026-04-10 | 11:23 ET | [DEF 14A](/filings/0001140361-26-014157.md) | Proxy statement, period 2026-05-21 | 0001140361-26-014157 | | 2026-03-02 | 16:49 ET | [10-K](/filings/0001193125-26-085584.md) | Annual report, period 2025-12-31 | 0001193125-26-085584 | | 2026-03-02 | 16:22 ET | [8-K](/filings/0001193125-26-085474.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-085474 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-085584.md), filed Mar 2, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/af18f038-4af2-44ad-b03f-f10bcde8290e) ## About the filer - CIK: 1811063 - Tickers: NUVB - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.